Klf5 function in normal and leukaemic haemopoiesis

Klf5 在正常和白血病造血中的功能

• 批准号: nhmrc : 626946
• 负责人: A/Pr Ian Lewis
• 金额: $ 40.67万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/klf5-function-normal-leukaemic-haemopoiesis/76806
• 关键词: Klf5; function; normal; leukaemic; haemopoiesis

Acute Myeloid Leukaemia (AML) is a devastating disease that affects both children and adults. New treatments that target particular genetic abnormalities are urgently needed. We have identified KLF5 as a gene that may control blood cell maturation. In AML patient samples we have found alterations of the KLF5 gene that may suppress its activity and contribute to the formation of leukaemia. These leukaemias may be good candidates for treatment with new drugs called methyltransferase inhibitors.

急性骨髓性白血病（AML）是一种影响儿童和成人的毁灭性疾病。针对特定遗传异常的新疗法是迫切需要的。我们已经确定KLF5是一个可能控制血细胞成熟的基因。在AML患者样本中，我们发现KLF5基因的改变可能抑制其活性并有助于白血病的形成。这些白血病可能是用一种叫做甲基转移酶抑制剂的新药治疗的好的候选者。